|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
The European Pharmacopoeia specifies a limit of fewer than 100 microorganisms per ml for nasal preparations. The Pharmacopoeia also recommends that nasalia should neither cause irritations nor have any adverse effects. Unfortunately, several common preservatives may impair the functioning of the nasal mucosa or the cilia, so for health reasons the use of preservatives should be avoided whenever possible. If nasal preparations are used by long-term users, such as patients with chronic diseases, allergies, or consumers in air-conditioned surroundings, then the avoidance of preservatives is a particularly sustainable therapeutic
improvement.
The possibility of preservative-free but microbiologically safe applications of nasalia is possible via certain systems, which have been designed specifically for the requirements of preservative-free applications. In Germany, preservative-free systems are developing rapidly and serve as a model for other types of preparation. Moreover, the nasal application of systemic drugs in new indications (such as hormone therapy, analgesics and motion
sickness) might play a significant role in future developments.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Biovian expands - and invests in new capacity
More info >> |
|
 |
